Litcius/Paper detail

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis

David Baker, Amy MacDougall, Angray S. Kang, Klaus Schmierer, Gavin Giovannoni, Ruth Dobson

2021Multiple Sclerosis and Related Disorders29 citationsDOIOpen Access PDF

Topics & Concepts

OcrelizumabCladribineMedicineAlemtuzumabMultiple sclerosisInternal medicineImmunologyDosingOncologyRituximabTransplantationAntibodyMultiple Sclerosis Research StudiesSARS-CoV-2 and COVID-19 ResearchPeripheral Neuropathies and Disorders
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis | Litcius